Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

DES Best for In-Stent Restenosis, but DCBs Also Viable

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.